{"entity":{"id":"idea-data-linked-pharmacovigilance-interactions","kind":"idea","name":"Linked prescribing and outcome data to find drug interactions with cancer therapy","aka":[],"tldr":"Use joined-up pharmacy and hospital records to spot when a common everyday medicine makes a cancer drug work worse or cause more harm.","summary":"Interactions between anticancer agents and common co-medications (proton pump inhibitors with some kinase inhibitors and capecitabine; antibiotics and steroids with immunotherapy) have emerged from retrospective analyses years after approval. The proposal is a standing surveillance system using linked prescribing and outcome data that screens all new oncology drugs against the 200 most common co-medications, with signals triaged to confirmatory analysis or trials.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)","url":"https://doi.org/10.1001/jamainternmed.2019.0462"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":[],"bottlenecks":["b-real-world-evidence","b-toxicity-qol"],"keyPapers":["paper-gyawali-jama-intern-med"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Systematic screening will detect clinically relevant interactions for new drugs within 18 months of approval, compared with a historical median of several years.","rationale":"The PPI and capecitabine signal and the antibiotic and immunotherapy signal were both found in retrospective trial and registry analyses; a systematic screen would have found them sooner.","test":"Run the screen on five drugs approved three or more years ago; check whether it rediscovers known interactions and how many new signals it produces; validate the top signals in independent data.","maturity":"early-clinical","actor":"data","cost":"small","horizonYears":2},"route":"/ideas/idea-data-linked-pharmacovigilance-interactions/","neighbours":{"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"}],"term":[{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/"}],"bottleneck":[{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/"}],"paper":[{"id":"paper-gyawali-jama-intern-med","kind":"paper","name":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval","route":"/key-papers/paper-gyawali-jama-intern-med/"}]}}